The result of application of the simple CHAMPION trial protocol illustrated in Figure 5 was a significant reduction in HF hospitalizations.^[3]  Over the entire period of the randomized, single-blind, controlled follow-up, there was a 33% reduction in the risk of HF hospitalizations.  But importantly, beyond that there was also a significant reduction in the combined endpoint of death from any cause or HF hospitalizations, and [indicated by the red outline] there were also significant reductions in all-cause hospitalizations and in the composite of all-cause death or all-cause hospitalizations.  This latter observation is important because it shows that there is no trade-off with PAP-guided HF therapy; ie, there is no increase in other types of hospitalizations associated with the reduction in HF hospitalizations.  In other words, use of PAP-guided HF therapy results in a win in terms of the effects on both HF morbidity and mortality.